

News

Welcome to the third PREVENTT newsletter. It has been another productive month in the PREVENTT office as hospital set up continues to progress at a number of sites. During October, site initiation visits were completed at both Hillingdon and Maidstone hospitals. Thank you to Cheryl Messer and Andrew Taylor and their teams for their time during the site visits.

The eCRF is also now live and ready for use by sites and login details will be sent to blinded members of the trial team at sites open to recruitment. Training can be arranged for any centres if required and a detailed SOP will be sent to all sites.

PREVENTT Site Update

	Site Name	Update
10	UCLH	Open to recruitment
11	Royal Free Hospital	Local R&D application started
12	Royal Cornwall	Open to recruitment
13	Royal Devon and Exeter	Local R&D application started
14	Royal Marsden	Local R&D application started
15	QEH King's Lynn	Local R&D application started
16	Hillingdon Hospital	Open to recruitment
17	Morrison Hospital	Reviewing Trial Documentation
18	York Hospital	Local R&D approval received– site initiation on 22/11/2013
19	Dorset County Hospital	Local R&D approval received– site initiation on 04/12/2013
20	Maidstone Hospital	Open to recruitment
21	Freeman Hospital, Newcastle	Local R&D application started
22	Southmead Hospital	Local R&D application started
23	Royal London Hospital	Local R&D application started
24	Northern General, Sheffield	Local R&D approval received– site initiation on 22/11/2013
25	Southampton General Hospital	Local R&D application started
27	Bristol Royal Infirmary	Local R&D application started– site initiation on 03/12/2013
29	Royal Sussex County Hospital	Local R&D application started
29	Royal Bournemouth Hospital	Reviewing Trial Documentation
30	St James' Hospital, Leeds	Reviewing Trial Documentation
32	Guy's and St Thomas'	Reviewing Trial Documentation

If you have any questions about the trial and set up at your centre, please get in touch with the PREVENTT office.

Frequently Asked Question:

Q. The protocol states that the drug administration must occur 14-42 days before surgery. Many cancer patients will be operated on within two weeks. When would the various visits occur?

A. The patient pathway will be different for each hospital. Specifically for cancer patients, there are several routes where they may be identified and screened: through a GP letter at an endoscopy appointment, on referral for a CT or MRI (as normally the patient has had bloods checked for these investigations) or at a MDT. Cancer patients will also often be seen many times before their surgery at various different appointments (clinic, MDT) and these could be utilised and trial visits incorporated.

It may also be useful to go through waiting lists, to identify potential patients earlier.

Site Initiation Visits

Site visits have now been held at four hospitals; UCLH, Royal Cornwall Hospital, Hillingdon Hospital and Maidstone Hospital. The main reason for the initiation visit is to train the PREVENTT staff in the intervention and randomisation procedures and to go through the site files in detail.

A short presentation on PREVENTT is given at the start and we have found that it is very helpful if the PI is present for this as a number of questions often arise. As the trial also involves pharmacy, it is helpful to meet the pharmacist as well. It is extremely enjoyable and valuable for us to meet the research nurses and team that are involved with PREVENTT face to face.

Screening Logs

Following site initiation, we will ask when it is likely the site will start screening for eligible patients. At this point you will be asked to begin filling out a screening log, which should include all patients undergoing major abdominal surgery (open or laparoscopic). The log should include details of whether the patients were recruited into PREVENTT. If not recruited the reason why not should be included.

The log will need to be submitted to the coordinating centre at the end of each month. The information provided is then reviewed at the project management meetings, which meet at least twice a month. The screening log provides valuable information with regard to why patients are not being recruited into the trial. This might be used as a basis for a change in exclusion criteria.

If patients are refusing then please provide as much information as to the reasons why.

Meet the PREVENTT Team

This Month: Matthew Dodd, Data Manager

Hi everyone! I'm Matt and I've recently started working at LSHTM in the PREVENTT office. I will be completing administrative and data management tasks for the trial, and will be responsible for processing screening log data. Previously I have worked at Loughborough University performing research in sport, exercise and health sciences. I look forward to being part of the PREVENTT team and getting to know you all better!



Contact Information

Website: <http://preventt.lshtm.ac.uk/>

Tel: +44 (0)20 7927 2071

Fax: +44 (0)20 7927 2189

Email: preventt@lshtm.ac.uk/rebecca.swinson@lshtm.ac.uk